Shagun Singh
Stock Analyst at RBC Capital
(2.29)
# 2,224
Out of 4,804 analysts
192
Total ratings
37.79%
Success rate
-4.7%
Average return
Main Sectors:
Stocks Rated by Shagun Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Reiterates: Outperform | $181 | $150.97 | +19.89% | 19 | Apr 3, 2025 | |
| ZYXI Zynex | Downgrades: Sector Perform | $11 → $5.5 | $2.35 | +134.04% | 6 | Mar 12, 2025 | |
| PODD Insulet | Initiates: Outperform | $340 | $264.72 | +28.44% | 1 | Mar 6, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $65 → $55 | $17.61 | +212.32% | 2 | Feb 27, 2025 | |
| MDT Medtronic | Reiterates: Outperform | $105 | $85.28 | +23.12% | 20 | Feb 19, 2025 | |
| PEN Penumbra | Maintains: Outperform | $285 → $313 | $275.46 | +13.63% | 11 | Feb 19, 2025 | |
| EW Edwards Lifesciences | Reiterates: Outperform | $85 | $69.90 | +21.60% | 21 | Feb 12, 2025 | |
| INSP Inspire Medical Systems | Reiterates: Outperform | $260 | $153.81 | +69.04% | 4 | Feb 11, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $125 | $103.44 | +20.84% | 13 | Feb 7, 2025 | |
| BSX Boston Scientific | Maintains: Outperform | $105 → $116 | $96.77 | +19.87% | 14 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $425 → $435 | $362.97 | +19.84% | 19 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $135 | $127.04 | +6.27% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $45 | $9.94 | +352.72% | 9 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $92 | $74.28 | +23.86% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $245 | $135.16 | +81.27% | 19 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $115 | $66.84 | +72.05% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $525 → $555 | $522.95 | +6.13% | 13 | Oct 18, 2024 |
Johnson & Johnson
Apr 3, 2025
Reiterates: Outperform
Price Target: $181
Current: $150.97
Upside: +19.89%
Zynex
Mar 12, 2025
Downgrades: Sector Perform
Price Target: $11 → $5.5
Current: $2.35
Upside: +134.04%
Insulet
Mar 6, 2025
Initiates: Outperform
Price Target: $340
Current: $264.72
Upside: +28.44%
Tandem Diabetes Care
Feb 27, 2025
Maintains: Outperform
Price Target: $65 → $55
Current: $17.61
Upside: +212.32%
Medtronic
Feb 19, 2025
Reiterates: Outperform
Price Target: $105
Current: $85.28
Upside: +23.12%
Penumbra
Feb 19, 2025
Maintains: Outperform
Price Target: $285 → $313
Current: $275.46
Upside: +13.63%
Edwards Lifesciences
Feb 12, 2025
Reiterates: Outperform
Price Target: $85
Current: $69.90
Upside: +21.60%
Inspire Medical Systems
Feb 11, 2025
Reiterates: Outperform
Price Target: $260
Current: $153.81
Upside: +69.04%
Zimmer Biomet Holdings
Feb 7, 2025
Maintains: Outperform
Price Target: $130 → $125
Current: $103.44
Upside: +20.84%
Boston Scientific
Feb 6, 2025
Maintains: Outperform
Price Target: $105 → $116
Current: $96.77
Upside: +19.87%
Jan 29, 2025
Maintains: Outperform
Price Target: $425 → $435
Current: $362.97
Upside: +19.84%
Jan 23, 2025
Reiterates: Outperform
Price Target: $135
Current: $127.04
Upside: +6.27%
Jan 7, 2025
Reiterates: Sector Perform
Price Target: $45
Current: $9.94
Upside: +352.72%
Nov 6, 2024
Maintains: Outperform
Price Target: $80 → $92
Current: $74.28
Upside: +23.86%
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $245
Current: $135.16
Upside: +81.27%
Oct 25, 2024
Maintains: Outperform
Price Target: $120 → $115
Current: $66.84
Upside: +72.05%
Oct 18, 2024
Maintains: Outperform
Price Target: $525 → $555
Current: $522.95
Upside: +6.13%